A Postmarket Surveillance Study of the Paradigm Spine Dynamic Stabilization System (DSS)

NCT01461005 — Not applicable, Terminated, 1 participants, Paradigm Spine

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

A Postmarket Surveillance Study of the Paradigm Spine Dynamic Stabilization System(DSS)

RegistryNCT01461005, acronym DSS
StatusTerminated - FDA reclassified so all 522 studies were stopped,
PhaseNot applicable
Study typeInterventional; na, single group, masking: none, treatment
Enrollment1 (Actual)
SponsorParadigm Spine (Industry); collaborators: MCRA
ConditionsSpondylolisthesis, Neurologic Deficits, Kyphosis, Pseudarthrosis
InterventionsDynamic Stabilization System (DSS) (Device)
Datesstart 2011-09-01, primary completion 2016-09-01, completion 2016-09-01, first posted 2011-10-27, last updated 2020-02-19
Locations1 site in United States

Related Papers Related Patents Related Grants Related Experts
All trials for Spondylolisthesis All trials for Neurologic Deficits All trials of Dynamic Stabilization System (DSS)

-Summary

The purpose of the Post-Market Surveillance study is to evaluate safety.

Expand all sections  ·  Collapse all

+Detailed description

Paradigm Spine Dynamic Stabilization System (DSS) study is a prospective, multi-center, literature controlled study.

+Arms and interventions

ArmTypeInterventionsDescription
Dynamic Stabilization SystemExperimentalDevice: Dynamic Stabilization System (DSS)Dynamic Stabilization System (DSS) System
  • Dynamic Stabilization System (DSS) (Device): Dynamic Stabilization System

+Outcome measures

Primary outcomes

  • Number of Participants Who Have an Incidence of Serious or Device Related Adverse Events Due to Device or Procedure. [6 months]: The safety endpoint is defined as the incidence of serious or device related adverse events attributable to the device or procedure. Reoperations, revisions or removals of the Dynamic Stabilization System (DSS) System implant will be evaluated.

Secondary outcomes

  • Measurement of Lower Back Pain as Assessed by Visual Analog Scale [6 months]: Lower back pain as measured by the Visual Analog Scale (VAS) on the scale from 0 (no pain) to 100 (worst imaginable pain)
  • Measurement of Right Leg Pain as Assessed by Visual Analog Scale [6 months]: Right leg pain as measured by the Visual Analog Scale (VAS) on the scale from 0 (no pain) to 100 (worst imaginable pain)
  • Measurement of Left Leg Pain as Assessed by Visual Analog Scale [6 months]: Left leg pain as measured by the Visual Analog Scale (VAS) on the scale from 0 (no pain) to 100 (worst imaginable pain)
  • Number of Participants With Improved Health as Measured by the EuroQOL Health Related Qualify of Life- 5 Dimensions-3 Level (EQ-5D-3L) Health Questionnaire Compared to Baseline. [Pre-Op, 6 weeks, 6 months, 12 months, and 24 months]: The EQ-5D-3L is a standardized instrument used as a measure of health outcomes. It contains questions in 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and provides a simple descriptive profile and single index for health status preference. In addition, there is a Visual Analog Scale (VAS). The VAS is the participant's rating of their health on a scale of 0 "worst imaginable health state" to 100 "best imaginable health state".
  • Assessment of Back Pain Using the Oswestry Low Back Pain Disability Index (ODI). [6 months]: ODI is a questionnaire that provides information on back and the affects on managing every day life by diving questions into 10 sections. The total possible score for each section is 0-5. The scores are then converted into percentages ranging from 0% (minimal disability) to 100% (maximum possible disability).

+Eligibility

Sex: All, ages: 21 Years to 85 Years

Inclusion Criteria:

* Patient is skeletally mature (21-85 years old).
* Patient has degenerative spondylolisthesis (Grade 1-3) with objective evidence of neurologic impairment, kyphosis, and/or failed previous fusion (pseudarthrosis) at index level.
* Capable and willing to comply with the requirements unique to the study, adhere to the post-operative treatment and management program, and return for required follow-up examinations.
* Surgeon has determined that DSS™ System is an appropriate treatment for the patient without regard to the study.

Exclusion Criteria:

* The need for interbody cages, allograft, or any other assistance during surgery. Device is only to be used with autograft per FDA approved indications.
* Any medical, mental or surgical condition precluding the potential benefit of spinal surgery or surgery in general.
* Acute or chronic systemic, spinal or localized infections.
* Active, severe systemic and metabolic diseases.
* Obesity defined as Body Mass Index > 35.
* Subject is pregnant or interested in becoming pregnant in the next 36 months.
* Dependency on pharmaceutical drugs, drug abuse, or alcoholism.
* Lack of patient cooperation.
* Foreign body sensitivity to the implant material.
* Degenerative scoliosis greater than 25 degrees.
* Grade 4 degenerative spondylolisthesis (>75% slip).
* Significant osteopenia A screening questionnaire for osteopenia, SCORE (Simple Calculated Osteoporosis Risk Estimation), will be used to screen patients who require a DEXA bone mineral density measurement. If DEXA is required*, exclusion will be defined as a DEXA bone density measured T score of ≤ -1.0 (The World Health Organization definition of osteopenia).
* Soft tissue deficit not allowing wound closure.
* Congenital abnormalities, tumors or other conditions that would prevent secure component fixation that has the potential to decrease the useful life of the device.
* Inadequate pedicles or vertebral body geometry of the thoracic, lumbar and sacral vertebrae.
* Bony lumbar spinal stenosis not related to the primary degenerative spondylolisthesis indication.
* Pars defect.
* Clinically compromised vertebral bodies at affected level due to current or past trauma.
* Prisoner or ward of the state.
* Currently in litigation regarding a spinal condition.
* Known allergy to titanium, titanium alloys, CoCrMo, polyethylene or MR contrast agents.
* Is currently involved in a study of another investigational product for similar purpose.

+Posted results

Participant flow

MilestoneDynamic Stabilization System
Started1
Completed0
Not completed1

Outcome results

  • Number of Participants Who Have an Incidence of Serious or Device Related Adverse Events Due to Device or Procedure. (Primary), Count of participants, Participants: Dynamic Stabilization System 0
  • Measurement of Lower Back Pain as Assessed by Visual Analog Scale (Secondary), Number, units on a scale: Dynamic Stabilization System 2
  • Measurement of Right Leg Pain as Assessed by Visual Analog Scale (Secondary), Number, units on a scale: DSS Stabilization System 2
  • Measurement of Left Leg Pain as Assessed by Visual Analog Scale (Secondary), Number, units on a scale: DSS Stabilization System 12
  • Number of Participants With Improved Health as Measured by the EuroQOL Health Related Qualify of Life- 5 Dimensions-3 Level (EQ-5D-3L) Health Questionnaire Compared to Baseline. (Secondary), Number, participants: DSS Stabilization System 1
  • Assessment of Back Pain Using the Oswestry Low Back Pain Disability Index (ODI). (Secondary), Number, score on a scale: DSS Stabilization System 2

Adverse events

Time frame: 6 months

ArmDeathsSerious adverse eventsOther adverse events
Dynamic Stabilization System00/1 (0.0%)0/1 (0.0%)

+Locations (1)

FacilityCityCountryStatus
University of California, Davis Medical CenterSacramento, CaliforniaUnited States

+Investigators